Mission Therapeutics’ strategy is to create value by advancing its pipeline program through early clinical development, preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programs may be advanced in partnership with other pharmaceutical companies.
Through application of our DUB platform, we have the potential to explore multiple additional DUB targets relevant to other diseases, in strategic partnerships with other pharmaceutical companies or academics.
- Mission Therapeutics’ Highlights Positive Parkinson’s Disease USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting16th November 2017
- Mission Therapeutics’ Scientists Presenting Novel Parkinson’s USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting1st November 2017
- Mission Therapeutics Presenting at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference30th October 2017